C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.

NCT ID: NCT07250724

Last Updated: 2026-01-12

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2026-02-01
• Study Completion Date: 2026-10-15

Brief Summary

Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations".

The goal of this study is to map the risk of having a C. Difficile infection recurrence (rCDI) after being treated with standard-of-care antibiotics for a C. Difficile infection.

The main questions it aims to answer are:

• What is the recurrence rate of CDI in the 8 weeks following antibiotic treatment for a first recurrence of CDI?
• Does toxin levels of Toxin A and/or B from C. Diff. at baseline predict CDI recurrence risk?

Participants will:

• Undergo standard of care Antibiotic treatment for first recurrence of CDI
• Visit their clinic at 4 different visits over a time period of approximately 9 weeks. (Visits can also be performed remote/via phone call.)

Detailed Description

Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations".

This prospective observational study will enrol 60 otherwise healthy adults with a documented history of first recurrent Clostridioides difficile infection (rCDI). Eligible participants must have had a confirmed positive toxin B test for C. difficile, with the initial infection occurring within the past 12 months. At the time of enrolment (Day 0), participants must have completed a standard-of-care oral antibiotic therapy for their first rCDI no more than five days prior and be asymptomatic for CDI. Potential participants will sign an informed consent form at their initial visit to their doctor (visit 1) and provide a stool sample for c diff testing. Participants will only be considered 'enrolled' if their stool sample is positive for toxin B and they meet all other criteria at visit 2 (week 0).

The primary objective of the study is to measure the rate of CDI recurrence within an 8-week follow-up period. The secondary objective is to assess stool levels of Toxin A and B at baseline, week 2, and week 8. The second objective will enable exploration of the reliability of using high-sensitivity assays for toxin detection in stool. Further, potential correlations between post-treatment stool toxin levels and rCDI development will be explored.

Conditions

Clostridioides Difficile Infection Recurrence

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.

Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Able to provide signed and dated informed consent
• Males and females between 18 - 75 years old inclusive
• Documented history of first recurrent Clostridioides difficile (former Clostridium difficile) infection (rCDI), confirmed by a positive C. difficile test (Toxin A+B positive or Toxin B only), with initial infection occurring within the previous 12-months.
• Must, in accordance with standard of care practices, have completed a SOC oral antibiotic therapy for the first rCDI no more than 5 days prior to the date of enrolment (baseline visit- Day 0).
• Must not have any CDI-related symptoms when enrolled in the study at baseline (Day 0).

Exclusion Criteria

• Current episode of CDI or delayed symptom resolution from previous recurrence, according to the physical exam and investigator assessment
• Toxin A positive, and Toxin B negative C. difficile test.
• Planned CDI recurrence treatment for the duration of the study e.g., fecal microbiome transplant, probiotics, Live Biotherapeutic Products (LBPs)
• Those who are on further antibiotic treatment following initial rCDI antibiotic therapy completion.
• Pregnant or lactating women or women who intend to become pregnant within the next 3 months.
• Subjects presenting with active diarrhoea (3 or more stools per 24-hour period) and within Bristol stool scale range of 5-7 at baseline.
• Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results.

• Ostomized participants, parenteral nutrition users
• Patients with active Pancreatitis
• Active, non-controlled intestinal diseases such as IBS, IBD, Crohn's Disease, ulcerative colitis, celiac disease, or other chronic diarrheal illness
• Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results.
• Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
• Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bactolife A/S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Brynjulf Mortensen, pHD

Role: STUDY_DIRECTOR

Bactolife A/S

Locations

Emory University Hospital

Atlanta, Georgia, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Kevin O' Regan Senior Operations Manager, Atlantia Clinical Trials

Role: CONTACT

koregan@atlantiatrials.com

+1 312 818 8905

Facility Contacts

Jennifer C Truell, MA, MPH

Role: primary

jennifer.carter.truell@emory.edu

404-778-0014

Colleen S Kraft, MD

Role: backup

colleen.kraft@emory.edu

404-712-8889

Other Identifiers

AFCRO-193

Identifier Type: -

Identifier Source: org_study_id